nach oben

Current Cardiology Reports

Erschienen in:

07.02.2022 | New Therapies for Cardiovascular Disease (AA Bavry and MR Massoomi, Section Editors)

AngioVac for Minimally Invasive Removal of Intravascular and Intracardiac Masses: a Systematic Review

verfasst von: Tariq Enezate, Deya Alkhatib, Joel Raja, Viswanatha Chinta, Mitul Patel, Jad Omran

Erschienen in: Current Cardiology Reports | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Management of intracardiac masses, such as right heart thrombi and catheter-related vegetations, can be challenging. Many patients are high-risk candidates for surgical extraction due to multiple comorbidities and risk of distal embolization. In this review, we highlight the advancements in percutaneous approaches for treatment of intracardiac masses utilizing AngioVac (AngioDynamic, Latham, NY).

Recent Findings

With the Food and Drug Administration (FDA) approval of the AngioVac System in 2009, a growing body of evidence has proven it to be a feasible and effective tool to extract thrombi and masses from the iliocaval system and the right heart.

Summary

In this review, we highlight the feasibility of AngioVac System (AngioDynamic, Latham, NY) based on the published cases series and registries. Future randomized controlled trials are needed to establish an algorithmic approach in treating intracardiac masses.

Enezate TH, Kumar A, Aggarwal K, Balla S, Omran J. Non-surgical extraction of right atrial mass by AngioVac aspiration device under fluoroscopic and transesophageal echocardiographic guidance. Cardiovasc Diagn Ther. 2017;7(3):331–5. https://doi.org/10.21037/cdt.2016.09.03.CrossRefPubMedPubMedCentral

Behrens G, Bjarnason H. Venous thromboembolic disease: the use of the aspiration thrombectomy device AngioVac. Semin Intervent Radiol. 2015;32(4):374–8. https://doi.org/10.1055/s-0035-1564792.CrossRefPubMedPubMedCentral

Donaldson CW, Baker JN, Narayan RL, et al. Thrombectomy using suction filtration and veno-venous bypass: single center experience with a novel device. Catheter Cardiovasc Interv. 2015;86(2):E81–7. https://doi.org/10.1002/ccd.25583.CrossRefPubMed

Al Badri A, Kliger C, Weiss D, et al. Right atrial vacuum-assisted thrombectomy: single-center experience. J Invasive Cardiol. 2016;28(5):196–201.PubMed

Rose PS, Punjabi NM, Pearse DB. Treatment of right heart thromboemboli. Chest. 2002;121(3):806–14. https://doi.org/10.1378/chest.121.3.806.CrossRefPubMed

• Resnick SA, O'Brien D, Strain D, et al. Single-center experience using AngioVac with extracorporeal bypass for mechanical thrombectomy of atrial and central vein thrombi. J Vasc Interv Radiol. 2016;27(5):723–9. https://doi.org/10.1016/j.jvir.2016.02.009. Findings from this single-center case series are assessing the usage of the AngioVac System in seven patients with large iliocaval thrombi or RHT between 2014 and 2015, the AngioVac System was successful in partial or complete clot removal, and all patients survived the procedure. Distal embolization of septic emboli occurred in one case.

Al-Hakim R, Park J, Bansal A, Genshaft S, Moriarty JM. Early experience with AngioVac aspiration in the pulmonary arteries. J Vasc Interv Radiol. 2016;27(5):730–4. https://doi.org/10.1016/j.jvir.2016.01.012.CrossRefPubMed

D’Ayala M, Worku B, Gulkarov I, Sista A, Horowitz J, Salemi A. Factors associated with successful thrombus extraction with the AngioVac device: an institutional experience. Ann Vasc Surg. 2017;38:242–7. https://doi.org/10.1016/j.avsg.2016.04.015.CrossRefPubMed

Pant S, Patel NJ, Deshmukh A, et al. Trends in infective endocarditis incidence microbiology and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol. 2015;65(19):2070–6. https://doi.org/10.1016/j.jacc.2015.03.518.CrossRefPubMed

10.

Diz DP. Infective endocarditis prophylaxis. Oral Dis. 2014;20(4):325–8. https://doi.org/10.1111/odi.12221.CrossRef

11.

Moreillon P, Que YA. Infective endocarditis. Lancet. 2004;363(9403):139–49. https://doi.org/10.1016/S0140-6736(03)15266-X.CrossRefPubMed

12.

Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply 2002–12. Health Aff. 2016;35(5):832–7. https://doi.org/10.1377/hlthaff.2015.1424.CrossRef

13.

George B, Voelkel A, Kotter J, Leventhal A, Gurley J. A novel approach to percutaneous removal of large tricuspid valve vegetations using suction filtration and veno-venous bypass: a single center experience. Catheter Cardiovasc Interv. 2017;90(6):1009–15. https://doi.org/10.1002/ccd.27097.CrossRefPubMed

14.

Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017;14(12):e503–51. https://doi.org/10.1016/j.hrthm.2017.09.001.CrossRefPubMed

15.

Patel N, Azemi T, Zaeem F, et al. Vacuum assisted vegetation extraction for the management of large lead vegetations. J Card Surg. 2013;28(3):321–4. https://doi.org/10.1111/jocs.12087.CrossRefPubMed

16.

Schaerf RHM, Najibi S, Conrad J. Percutaneous vacuum-assisted thrombectomy device used for removal of large vegetations on infected pacemaker and defibrillator leads as an adjunct to lead extraction. J Atr Fibrillation. 2016;9(3):1455. https://doi.org/10.4022/jafib.1455 Published 2016 Oct 31.CrossRefPubMedPubMedCentral

17.

Castillo JG, Silvay G. Characterization and management of cardiac tumors. Semin Cardiothorac Vasc Anesth. 2010;14(1):6–20. https://doi.org/10.1177/1089253210362596.CrossRefPubMed

18.

Patel J, Sheppard MN. Pathological study of primary cardiac and pericardial tumours in a specialist UK Centre: surgical and autopsy series. Cardiovasc Pathol. 2010;19(6):343–52. https://doi.org/10.1016/j.carpath.2009.07.005.CrossRefPubMed

19.

Roberts WC. Primary and secondary neoplasms of the heart. Am J Cardiol. 1997;80(5):671–82. https://doi.org/10.1016/s0002-9149(97)00587-0.CrossRefPubMed

20.

McAllister HA Jr. Primary tumors and cysts of the heart and pericardium. Curr Probl Cardiol. 1979;4(2):1–51. https://doi.org/10.1016/0146-2806(79)90008-2.CrossRefPubMed

21.

Tyebally S, Chen D, Bhattacharyya S, et al. Cardiac tumors: JACC CardioOncology State-of-the-Art Review. JACC CardioOncol. 2020;2(2):293–311. https://doi.org/10.1016/j.jaccao.2020.05.009 Published 2020 Jun 16.CrossRefPubMedPubMedCentral

22.

Lebehn M, Kampaktsis PN, Sethi S, Hamid N. Debulking of a large right heart mass in a cancer patient using the AngioVac System. Eur Heart J Case Rep. 2020;4(6):1–2. https://doi.org/10.1093/ehjcr/ytaa432 Published 2020 Dec 1.CrossRefPubMedPubMedCentral

23.

Bhagat A, Annie FH, Tager A, Nanjundappa A, Adams C. Alternative treatment approach for right heart masses. Cureus. 2018;10(12):e3673. https://doi.org/10.7759/cureus.3673 Published 2018 Dec 3.CrossRefPubMedPubMedCentral

24.

Minakawa M, Fukuda I, Miyata H, et al. Outcomes of pulmonary embolectomy for acute pulmonary embolism. Circ J. 2018;82(8):2184–90. https://doi.org/10.1253/circj.CJ-18-0371.CrossRefPubMed

25.

Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev. 2016;11(11):CD002783. https://doi.org/10.1002/14651858.CD002783.pub4 Published 2016 Nov 10.CrossRefPubMed

26.

Lang IM, Marsh JJ, Olman MA, Moser KM, Schleef RR. Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli. Circulation. 1994;90(2):706–12. https://doi.org/10.1161/01.cir.90.2.706.CrossRefPubMed

27.

•• Moriarty JM, Rueda V, Liao M, et al. Endovascular removal of thrombus and right heart masses using the AngioVac System: results of 234 patients from the prospective, multicenter Registry of AngioVac Procedures in Detail (RAPID). J Vasc Interv Radiol. 2021;32(4):549–57. https://doi.org/10.1016/j.jvir.2020.09.012. Findings from this study suggest that the AngioVac System was successful in 73.6%, 58.5%, 60%, and 57.1% of patients with caval thromboemboli, right heart mass, catheter-related thrombi, and PE, respectively.

28.

Hameed I, Lau C, Khan FM, et al. AngioVac for extraction of venous thromboses and endocardial vegetations: a meta-analysis. J Card Surg. 2019;34(4):170–80. https://doi.org/10.1111/jocs.14009.CrossRefPubMed

29.

Moriarty JM, Al-Hakim R, Bansal A, Park JK. Removal of caval and right atrial thrombi and masses using the AngioVac device: initial operative experience. J Vasc Interv Radiol. 2016;27(10):1584–91. https://doi.org/10.1016/j.jvir.2016.03.045.CrossRefPubMed

Titel: AngioVac for Minimally Invasive Removal of Intravascular and Intracardiac Masses: a Systematic Review
verfasst von: Tariq Enezate
Deya Alkhatib
Joel Raja
Viswanatha Chinta
Mitul Patel
Jad Omran
Publikationsdatum: 07.02.2022
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 4/2022
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-022-01658-9

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Vascular Closure: the ABC’s

Strategies for Imaging Metabolic Remodeling of the Heart in Obesity and Heart Failure

Is Sedentary Behavior a Novel Risk Factor for Cardiovascular Disease?

Artificial Intelligence to Improve Risk Prediction with Nuclear Cardiac Studies